Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

We report on manufacturing outcomes for 41 autologous polyclonal regulatory T cell (PolyTreg) products for 7 different Phase 1 clinical trials over a 10-year period (2011-2020). Data on patient characteristics, manufacturing parameters, and manufacturing outcomes were collected from manufacturing ba...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joanna Balcerek, Brian R. Shy, Amy L. Putnam, Lisa M. Masiello, Angela Lares, Florinna Dekovic, Luis Acevedo, Michael R. Lee, Vinh Nguyen, Weihong Liu, Sreenivasan Paruthiyil, Jingying Xu, Ashley S. Leinbach, Jeffrey A. Bluestone, Qizhi Tang, Jonathan H. Esensten
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	regulatory T cell manufacturing cGMP ex vivo expansion cellular therapy regulatory T cells Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/4fbc3387d354494ba9daa3d9eab90fba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

Ejemplares similares